ZD6474 (ZACTIMA™) Phase III Study in EGFR Failures
Completed · Phase 3
Conditions studied: Non-Small-Cell Lung Carcinoma
In brief
This study is being carried out to assess if adding ZD6474 to best supportive care (BSC) is more effective than best supportive care alone, for the treatment of patients with non-small cell lung cancer, whose disease has recurred after previous chemotherapy and an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI). ZD6474 is a new anti-cancer drug in development that works in a different way to standard chemotherapy drugs. It targets the growth of new blood vessels to a tumour and thereby might slow the rate at which the tumour may grow. Early studies indicate that ZD6474 has a positive effect on the time that a tumour may take to progress to a further stage. Approximately 930 patients will take part in this study. It will be conducted in hospitals and clinics in North and South America, Europe and Asia.
Key facts
- Study ID
- NCT00404924
- Run by
- Genzyme, a Sanofi Company
- People needed
- 1140
- Starts
- 2006-11-01
- Expected to finish
- 2014-11-01
- Last updated by the study team
- 2016-09-30
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Patients with Non-small cell lung cancer for which the standard cancer treatments of surgery, chemotherapy, radiation or other anticancer drugs are no longer appropriate treatments for you.
You may not qualify if…
- Patients who have had standard cancer treatments of surgery, chemotherapy or other systemic anti-cancer therapy within 4 weeks before start of study therapy.
- Three or more prior chemotherapy regimens.
- Significant cardiovascular events.
Where it is running
- Research Site — Germantown, Tennessee, United States
- Research Site — Bahía Blanca, Argentina
- Research Site — Ciudad de Buenos Aires, Argentina
- Research Site — La Plata, Argentina
- Research Site — Rosario, Argentina
- Research Site — San Miguel de Tucumán, Argentina
- Research Site — Santa Fe, Argentina
- Research Site — Fitzroy, Australia
- Research Site — Perth, Australia
- Research Site — St Leonards, Australia
- Research Site — Tugan, Australia
- Research Site — Woodville South, Australia
- Research Site — Linz, Austria
- Research Site — Salzburg, Austria
- Research Site — Vienna, Austria
- Research Site — Antwerp, Belgium
- Research Site — Brussels (Woluwé-St-Lambert), Belgium
- Research Site — Charleroi, Belgium
- Research Site — Edegem, Belgium
- Research Site — Ghent, Belgium
- Research Site — Leuven, Belgium
- Research Site — Liège, Belgium
- Research Site — Edmonton, Alberta, Canada
- Research Site — Oshawa, Ontario, Canada
- Research Site — Tucson, Arizona, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.